Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
March 6, 2006
- Bill to Amend PAL to Be Presented to Diet on March 10
March 6, 2006
- DSP's Ambisome to Be Approved for Import
March 6, 2006
- Astellas' Vesicare Recommended for Approval: CDFS
March 6, 2006
- Korosho to Move to Eliminate Provisional Delivery of Drugs
March 6, 2006
- REGULATORY NEWS IN BRIEF
March 6, 2006
- Bayer, Onyx Initiate PIII Lung Cancer Study Using Nexavar
March 6, 2006
- SEMIANAR
March 6, 2006
- Switch to Aromasin Maintains QOL of Breast Cancer Patients: IES Study
March 6, 2006
- Pfizer Japan to Appoint New President & CEO
March 6, 2006
- R&D NEWS IN BRIEF
March 6, 2006
- REGULATORY NEWS IN BRIEF
February 27, 2006
- Olympus: Medical, Life Science Businesses Show Growth in 1st 3 Qtrs
February 27, 2006
- US FDA Accepts NDA for Garenoxacin: Toyama Chemical
February 27, 2006
- NEW PRODUCTS
February 27, 2006
- Continuing Reform Essential to Stabilize Social Security Systems: Health Minister Kawasaki
February 27, 2006
- SELF-MEDICATION NEWS IN BRIEF
February 27, 2006
- Varied Reactions Shown to New Medical Fees
February 27, 2006
- Fresenius to Complete Seamless Production System for Dialyzers in Japan
February 27, 2006
- Korosho's NHI Pricing Reform Proposals Approved
February 27, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…